TRDA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TRDA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Entrada Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2024 was $0.0 Mil. Its Revenue for the three months ended in Mar. 2024 was $59.1 Mil.
Entrada Therapeutics's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Entrada Therapeutics's Gross Margin % for the three months ended in Mar. 2024 was N/A%.
The historical data trend for Entrada Therapeutics's COGS-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
COGS-to-Revenue | - | - | - | - | - |
Entrada Therapeutics Quarterly Data | |||||||||||||||||
Dec19 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
COGS-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Entrada Therapeutics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 129.013 | |
= | 0.00 |
Entrada Therapeutics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as
COGS to Revenue | = | Cost of Goods Sold | / | Revenue |
= | 0 | / | 59.12 | |
= | 0.00 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entrada Therapeutics (NAS:TRDA) COGS-to-Revenue Explanation
Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.
Entrada Therapeutics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:
Gross Margin % | = | 1 | - | COGS to Revenue |
= | 1 | - | Cost of Goods Sold / Revenue | |
= | 1 | - | 0 / 59.12 | |
= | N/A % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.
Thank you for viewing the detailed overview of Entrada Therapeutics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Dipal Doshi | director, officer: President and CEO | C/O AMICUS THERAPEUTICS, 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Kory James Wentworth | officer: Chief Financial Officer | 6 TIDE STREET, C/O ENTRADA THERAPEUTICS, BOSTON MA 02210 |
Nathan J Dowden | officer: Chief Operating Officer | 6 TIDE STREET, BOSTON MA 02210 |
Nerissa Kreher | officer: Chief Medical Officer | C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139 |
Gina Chapman | director | C/O CARGO THERAPEUTICS, INC., 1900 ALAMEDA DE LAS PULGAS, SUITE 350, SAN MATEO CA 94403 |
Natarajan Sethuraman | officer: Chief Scientific Officer | 6 TIDE STREET, BOSTON MA 02210 |
Bernhardt G Zeiher | director | ENTRADA THERAPEUTICS, INC., 6 TIDE STREET, BOSTON MA 02210 |
Baker Bros. Advisors Lp | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Todd Foley | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Felix Baker | 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
Baker Bros. Advisors (gp) Llc | 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
John F Crowley | director | C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512 |
Redmile Group, Llc | 10 percent owner | ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129 |
Mpm Bioventures 2018, L.p. | 10 percent owner | 450 KENDALL STREET, CAMBRIDGE MA 02142 |
From GuruFocus
By Tiesvg Tiesvg • 01-02-2023
By GuruFocus Research • 12-28-2023
By Marketwired • 11-07-2023
By Stock market mentor Stock market mentor • 02-04-2023
By Marketwired • 08-10-2023
By Stock market mentor Stock market mentor • 01-22-2023
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 03-29-2023
By GuruFocus Research • 09-16-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.